Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.
Advertisement

Related Content

Boxed Warning In Development For Procrit, Aranesp
Boxed Warning In Development For Procrit, Aranesp
Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp
Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp
Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
Roche Delays CERA Oncology Filing Until 2009

Topics

Advertisement
UsernamePublicRestriction

Register

PS065676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel